Optimum Investment Advisors acquired a new position in Aimmune Therapeutics Inc (NASDAQ:AIMT) in the fourth quarter, HoldingsChannel.com reports. The firm acquired 2,500 shares of the biotechnology company’s stock, valued at approximately $84,000.
Other hedge funds have also added to or reduced their stakes in the company. Marshall Wace North America L.P. purchased a new stake in shares of Aimmune Therapeutics during the first quarter valued at $32,000. FTB Advisors Inc. increased its stake in shares of Aimmune Therapeutics by 67.3% in the 4th quarter. FTB Advisors Inc. now owns 1,039 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 418 shares during the last quarter. Tower Research Capital LLC TRC bought a new stake in shares of Aimmune Therapeutics in the 3rd quarter valued at $38,000. IFP Advisors Inc raised its holdings in Aimmune Therapeutics by 23.9% during the fourth quarter. IFP Advisors Inc now owns 2,532 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 488 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in shares of Aimmune Therapeutics by 336.3% during the 2nd quarter. Bank of Montreal Can now owns 4,363 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 3,363 shares in the last quarter. 81.53% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have commented on AIMT. Credit Suisse Group cut shares of Aimmune Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the company from $31.59 to $30.00 in a research note on Friday, December 13th. Goldman Sachs Group set a $27.00 target price on Aimmune Therapeutics and gave the stock a “hold” rating in a report on Friday, October 25th. ValuEngine cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 3rd. BidaskClub downgraded Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Finally, Roth Capital upped their price objective on shares of Aimmune Therapeutics from to in a research report on Thursday. Six research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Aimmune Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $42.60.
Shares of NASDAQ:AIMT opened at $33.36 on Friday. Aimmune Therapeutics Inc has a one year low of $16.95 and a one year high of $37.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.64 and a quick ratio of 4.64. The company has a market cap of $2.08 billion, a price-to-earnings ratio of -8.64 and a beta of 0.02. The firm has a 50 day simple moving average of $32.64 and a 200 day simple moving average of $25.39.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.03). During the same quarter in the prior year, the firm posted ($0.89) EPS. As a group, analysts expect that Aimmune Therapeutics Inc will post -3.98 EPS for the current year.
Aimmune Therapeutics Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Recommended Story: Different Types of Derivatives
Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics Inc (NASDAQ:AIMT).
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.